

*SOURCE: Neptune Technologies & Bioresources Inc.*

## **ERRATUM - Neptune To Hold Conference Call**

**LAVAL, Quebec, Jan. 11, 2012** Neptune Technologies and Bioresources Inc. (Nasdaq: NEPT) (TSX: NTB) will be holding a conference call and webcast on Tuesday, January 17, 2012 at 4:30 pm ET.

In consideration of Martin Luther King Jr. Day, on Monday, January 16, Neptune has decided to move the conference call to Tuesday, January 17. After speaking with a number of key American shareholders, Neptune would like to respect their request to move the call date.

Main topics to be discussed on the call include:

- Third quarter and year-to-date financial results,
- Commercial progress,
- Plant expansion,
- IP strategy

Conference call hosts:

- Henri Harland, President & CEO
- André Godin, CFO

The webcast can be accessed in listen only mode, free of charge, by clicking the link below:

<http://investor.shareholder.com/media/index.cfm?c=ABEA-2FTYUQ&e=2&mediakey=00C91657CB563BC69C078A021724CDA6>

To access the conference call by phone within Canada & the U.S. the toll-free number is 1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.

### Conference call details:

Conference Topic: Neptune Technologies & Bioresources Conference Call

Conference ID: 42564568

Management will accept questions by telephone during the Q&A period at the end of the presentation. Questions can also be forwarded in advance or during the presentation to [f.harland@neptunebiotech.com](mailto:f.harland@neptunebiotech.com)

An archived recording of the webcast will be available on Neptune's website ([www.neptunebiotech.com](http://www.neptunebiotech.com)) two hours after the webcast.

### About Neptune Technologies & Bioresources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

### About Acasti Pharma Inc.

Acasti Pharma (TSXV: APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

### About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

*"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."*

#### **Neptune Contact:**

Neptune Technologies & Bioresources Inc.

André Godin, CFO

+1.450.687.2262

[a.godin@neptunebiotech.com](mailto:a.godin@neptunebiotech.com)

[www.neptunebiotech.com](http://www.neptunebiotech.com)

#### **Howard Group Contact:**

Dave Burwell

(888) 221-0915

[dabe@howardgroupinc.com](mailto:dabe@howardgroupinc.com)

[www.howardgroupinc.com](http://www.howardgroupinc.com)

###

*Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.*